Rapamycin Protects from Type-I Peritoneal Membrane Failure Inhibiting the Angiogenesis, Lymphangiogenesis, and Endo-MT

Rapamycin-induced G1 cell cycle arrest employs both TGF-β and Rb pathways

(2015) Amrita Chatterjee et al.   CANCER LETTERS

Interstitial Fibrosis Restricts Osmotic Water Transport in Encapsulating Peritoneal Sclerosis

(2015) J. Morelle et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: An update

(2015) Simona Gurzu   World Journal of Clinical Cases

Rapamycin Inhibits Lymphatic Endothelial Cell Tube Formation by Downregulating Vascular Endothelial Growth Factor Receptor 3 Protein Expression

(2015) Yan Luo et al.   NEOPLASIA

Rapamycin: One Drug, Many Effects

(2014) Jing Li et al.   Cell Metabolism

Lymphangiogenic factors, mechanisms, and applications

(2014) Wei Zheng et al.   JOURNAL OF CLINICAL INVESTIGATION

m-TOR inhibitors may be useful in the treatment of encapsulating peritoneal sclerosis (EPS)

(2014) Giovanni Maria Frascà et al.   JOURNAL OF NEPHROLOGY

Tamoxifen Ameliorates Peritoneal Membrane Damage by Blocking Mesothelial to Mesenchymal Transition in Peritoneal Dialysis

(2014) Jesús Loureiro et al.   PLoS One

The Endothelial-Mesenchymal Transition (EndMT) and Tissue Regeneration

(2014) Wenjing Yu et al.   Current Stem Cell Research & Therapy

Bleomycin induces endothelial mesenchymal transition through activation of mTOR pathway: a possible mechanism contributing to the sclerotherapy of venous malformations

(2013) Wei Zhang et al.   BRITISH JOURNAL OF PHARMACOLOGY

TGF- 1 Promotes Lymphangiogenesis during Peritoneal Fibrosis

(2013) H. Kinashi et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

The Spectrum of Podoplanin Expression in Encapsulating Peritoneal Sclerosis

(2013) Niko Braun et al.   PLoS One

Impact of Rapamycin on Peritoneal Fibrosis and Transport Function

(2012) T. Xu et al.   BLOOD PURIFICATION

Effect of sirolimus on the regression of peritoneal sclerosis in an experimental rat model

(2012) Mevlut Ceri et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

Rapamycin inhibits transforming growth factor β-induced peritoneal angiogenesis by blocking the secondary hypoxic response

(2011) Yoshimi Sekiguchi et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Blocking TGF- 1 Protects the Peritoneal Membrane from Dialysate-Induced Damage

(2011) J. Loureiro et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Angiogenesis in Peritoneal Dialysis

(2011) A.W.D. Stavenuiter et al.   KIDNEY & BLOOD PRESSURE RESEARCH

Emergence of the Phosphoinositide 3-Kinase-Akt- Mammalian Target of Rapamycin Axis in Transforming Growth Factor-β-Induced Epithelial-Mesenchymal Transition

(2010) Samy Lamouille et al.   CELLS TISSUES ORGANS

Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study

(2010) M. R. Korte et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Rapamycin Inhibition of the Akt/mTOR Pathway Blocks Select Stages of VEGF-A 164 –Driven Angiogenesis, in Part by Blocking S6Kinase

(2009) Qi Xue et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The Role of the Mammalian Target Of Rapamycin (mTOR) in Renal Disease

(2009) W. Lieberthal et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Smad3-dependent and -independent pathways are involved in peritoneal membrane injury

(2009) Pranali Patel et al.   KIDNEY INTERNATIONAL